![]() |
CrossRef Text and Data Mining |
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab |
Jung-Wee Park |
jbm. 2021;28(4):339-341. Published online November 30, 2021 DOI: https://doi.org/10.11005/jbm.2021.28.4.339 |
Insufficient Mitigation of Bone Loss by Zoledronic Acid after Treatment with Denosumab Zoledronic Acid after Treatment with Denosumab is Associated with Bone Loss within 1 Year Alendronic-acid/denosumab/zoledronic-acid OR13-02 Treatment with Zoledronic Acid Subsequent to Denosumab Cannot Fully Prevent Bone Loss Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases Denosumab after bone progression with zoledronic acid: a single center experience Zoledronic Acid Infusions Cut Treatment-Related Bone Loss Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study 1016: Randomized Trial of Denosumab Versus Zoledronic Acid in Prostate Cancer Patients with Bone Metastases and Elevated Bone Turnover Markers After Receiving Zoledronic Acid Therapy |